Company profile: Mariana Oncology
1.1 - Company Overview
Company description
- Provider of precision radiopharmaceuticals and radioligand therapeutics for solid tumors, including MC-339 for small cell lung cancer with an actinium-based payload. Offers an integrated discovery and development platform covering target biology, ligand discovery, and optimization, and theranostic approaches using the same ligand for therapy and diagnosis to confirm target engagement, guide patient selection, and optimize dosing.
Products and services
- Precision Radiopharmaceuticals: Targeted peptide-based radioligand therapeutics for solid tumor cancers, engineered to maximize tumor penetration while minimizing toxicity
- Radiopharmaceutical Discovery Platform: Integrated discovery and development engine for precision radiopharmaceuticals spanning target biology, ligand discovery, and optimization
- Theranostic Approaches: Same-ligand strategy utilizes identical molecules for therapeutic and diagnostic purposes, enabling target engagement confirmation, patient selection, and dose optimization.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mariana Oncology
Advesya
HQ: France
Website
- Description: Provider of therapies for difficult-to-treat cancers, focusing on immuno-oncology and hematological malignancies, leveraging biochemistry and molecular and cellular biology expertise. Offers ADV-101, a topoisomerase I inhibitor antibody-drug conjugate targeting IL-1RAP for esophageal cancer, delivering cytotoxic agents directly to cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advesya company profile →
Oncternal Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology treatments, developing a pipeline including ONCT-808, a ROR1-targeting autologous CAR T in Phase 1/2 for relapsed or refractory aggressive B-cell lymphoma; ONCT-534, a dual-action androgen receptor inhibitor for metastatic castration-resistant prostate cancer; and zilovertamab, a ROR1-targeting monoclonal antibody evaluated with other treatments for various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncternal Therapeutics company profile →
NBE Therapeutics
HQ: Switzerland
Website
- Description: Provider of oncology therapies based on proprietary antibody-drug conjugates, including SMAC-Technology enzymatic conjugation for site-specific ADC manufacturing, Transpo-mAb mammalian cell display antibody discovery, a PNU-159682 anthracycline toxin payload platform, immune-oncology ADCs that activate CD8 cytotoxic T cells, and the ROR1-targeting NBE-002 candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NBE Therapeutics company profile →
Modifi Bio
HQ: United States
Website
- Description: Provider of direct DNA modification cancer therapeutics, including orally delivered molecules that selectively kill cancer cells by modifying tumor DNA while preserving healthy cells. Products target cancers with DNA repair defects and MGMT deficiency, with applications in glioblastomas, gliomas, and potentially other MGMT-deficient tumor types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modifi Bio company profile →
Normunity
HQ: United States
Website
- Description: Provider of precision immuno-oncology medicines focused on immune normalizers—novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normunity company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mariana Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mariana Oncology
2.2 - Growth funds investing in similar companies to Mariana Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mariana Oncology
4.2 - Public trading comparable groups for Mariana Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →